Compare PFE & SYK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFE | SYK |
|---|---|---|
| Founded | 1849 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.6B | 141.2B |
| IPO Year | N/A | N/A |
| Metric | PFE | SYK |
|---|---|---|
| Price | $25.84 | $363.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 16 |
| Target Price | $27.18 | ★ $434.19 |
| AVG Volume (30 Days) | ★ 43.8M | 1.7M |
| Earning Date | 02-03-2026 | 01-29-2026 |
| Dividend Yield | ★ 6.74% | 0.98% |
| EPS Growth | ★ 131.89 | N/A |
| EPS | 1.73 | ★ 7.61 |
| Revenue | ★ $62,785,000,000.00 | $24,381,000,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $8.61 |
| P/E Ratio | ★ $14.78 | $47.25 |
| Revenue Growth | 3.89 | ★ 10.95 |
| 52 Week Low | $20.92 | $329.16 |
| 52 Week High | $27.69 | $406.19 |
| Indicator | PFE | SYK |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 53.52 |
| Support Level | $25.09 | $358.39 |
| Resistance Level | $25.89 | $365.44 |
| Average True Range (ATR) | 0.50 | 7.38 |
| MACD | 0.07 | 0.65 |
| Stochastic Oscillator | 91.34 | 70.44 |
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.